Imaging Recommendations for Suspected Pancreatic Cancer

Multiphase Contrast‑Enhanced CT

The American College of Radiology recommends a pancreatic‑protocol multiphase CT (pancreatic phase ≈ 35–45 s, portal phase ≈ 60–70 s) as the first‑line test for any patient in whom pancreatic cancer is suspected. 1
This protocol achieves a sensitivity of ~90 % and specificity of ~99 % for detecting solid pancreatic neoplasms. 1
For lesions smaller than 2 cm, sensitivity declines to ≈ 77 % even with optimal contrast technique. 1
Contrast‑enhanced CT can reveal suspicious abnormalities 3–6 months before a formal diagnosis, with a sensitivity of 86 %. 1

The most frequent early lesion is a solid hypodense focus with a median size of about 7 mm at detection. 1
Early ductal changes include dilation, abrupt narrowing, or cutoff of the main pancreatic duct. 1
Interruption of the common bile duct is a specific early sign of head‑region pancreatic cancer, particularly in patients with conjugated hyperbilirubinemia. [1][2]
Vascular involvement (encasement or invasion) and extrapancreatic soft‑tissue extension may also be visible on contrast CT. 1

If iodinated contrast cannot be used, the American College of Radiology advises proceeding directly to gadolinium‑enhanced MRI with MRCP. 2
Contrast‑enhanced MRI identifies pancreatic abnormalities in 35 % of high‑risk individuals, compared with 11 % for non‑contrast CT. 2
MRI protocols should include dynamic multiphase T1‑weighted sequences (arterial ≈ 35–45 s, portal ≈ 60–70 s, delayed ≈ 3–5 min) to assess both parenchymal and ductal disease.

When contrast CT shows suspicious but nondiagnostic findings, EUS is recommended for further lesion characterization and possible tissue acquisition, especially for lesions < 2 cm that are difficult to evaluate on CT. 2

Never rely on a non‑contrast CT for pancreatic evaluation; its sensitivity is insufficient for early cancer detection. 1
Do not depend solely on abdominal ultrasound, as it cannot visualize the entire pancreas and lacks adequate sensitivity for early PDAC. 1
Do not delay advanced imaging (contrast CT or MRI) in patients with conjugated hyperbilirubinemia even if ultrasound is normal, because small pancreatic lesions can cause biliary obstruction without an obvious mass. [1][2]

The 2025 ACR guidelines state that many early pancreatic ductal adenocarcinoma (PDAC) findings require or are better detected with intravenous (IV) contrast, making contrast‑enhanced CT the preferred initial imaging modality. 3
The guidelines explicitly advise never to order a non‑contrast CT when pancreatic cancer is suspected because its sensitivity is inadequate and can delay diagnosis. 3

A pancreatic protocol CT that includes both pancreatic (≈35‑45 s) and portal‑venous (≈60‑70 s) phases achieves ≈90 % sensitivity and ≈99 % specificity for detecting solid pancreatic neoplasms. 3
Sensitivity declines to ≈77 % for lesions smaller than 2 cm, even when optimal contrast technique is used. 3
When evaluating early radiologic signs, contrast‑enhanced CT can identify suspicious findings 3–6 months before formal diagnosis with ≈86 % sensitivity. 4

The most common early feature is a hypodense solid lesion with a median size of about 7 mm at detection. 5
Other early signs that are only visible after contrast administration include:

In high‑risk cohorts, non‑contrast CT identified pancreatic abnormalities in only ≈11 % of subjects (mean lesion size ≈0.5 cm), whereas MRI detected ≈35 % and endoscopic ultrasound (EUS) detected ≈42 %. This underscores the limited utility of non‑contrast imaging for screening. 3

Step 1: Order a multiphase pancreatic protocol CT with IV contrast (pancreatic phase 35–45 s, portal‑venous phase 60–70 s). 4
Step 2: If IV contrast is contraindicated, proceed directly to MRI with IV gadolinium and MRCP, which provides superior detection in screening (≈35 % vs. ≈11 % for CT). 4
Step 3: Do not accept non‑contrast CT as adequate for pancreatic evaluation under any circumstance. 6